Celltech Reveals Plans for OGS: Proteomics Unit to be Divested, Parts of Oncology to Stay | GenomeWeb

After winning the bidding war for Oxford GlycoSciences in April, Celltech announced its proteomics division will be divested, in presenting its plans for the company at its annual general meeting last month. Meanwhile, the integration of OGS’ business is going full steam ahead.

As of last week, Celltech was close to owning 90 percent of OGS’ shares, according to Richard Bungay, Celltech’s director for corporate communications and strategic planning. Once the company owns 90 percent of the shares, it can force the remaining shareholders to sell.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.